SAB BIOTHERAPEUTICS, INC. Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price
SAB BIOTHERAPEUTICS, INC. (SABS) reported Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price of $4.39 per share for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice · last filed 2026-08-06
- SAB BIOTHERAPEUTICS, INC. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for the quarter ending 2026-03-31 was $4.43.
- SAB BIOTHERAPEUTICS, INC. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for the quarter ending 2024-03-31 was $5.15, a 853.70% increase year-over-year.
- SAB BIOTHERAPEUTICS, INC. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for the quarter ending 2023-03-31 was $0.54, a 90.43% decline year-over-year.
- SAB BIOTHERAPEUTICS, INC. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for the quarter ending 2022-03-31 was $5.64.
- SAB BIOTHERAPEUTICS, INC. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for fiscal 2025 was $2.37, a 40.60% decline from fiscal 2024.
- SAB BIOTHERAPEUTICS, INC. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for fiscal 2024 was $3.99, a 35.65% decline from fiscal 2023.
- SAB BIOTHERAPEUTICS, INC. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for fiscal 2023 was $6.20, a 302.60% increase from fiscal 2022.
- SAB BIOTHERAPEUTICS, INC. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for fiscal 2022 was $1.54, a 73.49% decline from fiscal 2021.
| Period end | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 3 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 6 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 9 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 12 month |
|---|---|---|---|---|
| 2026-06-30 | $4.39 10-Q · filed 2026-08-06 | |||
| 2026-03-31 | $4.43 10-Q · filed 2026-05-12 | |||
| 2025-12-31 | $2.37 10-K · filed 2026-03-09 | |||
| 2025-09-30 | $2.16 10-Q · filed 2025-11-14 | |||
| 2025-06-30 | $1.67 10-Q · filed 2025-08-07 | |||
| 2024-12-31 | $3.99 10-K · filed 2025-03-31 | |||
| 2024-09-30 | $3.90 10-Q · filed 2024-11-06 | |||
| 2024-06-30 | $5.13 10-Q · filed 2024-08-08 | |||
| 2024-03-31 | $5.15 10-Q · filed 2024-05-20 | |||
| 2023-12-31 | $6.20 10-K · filed 2024-03-29 | |||
| 2023-09-30 | $0.57 10-Q · filed 2023-11-13 | |||
| 2023-06-30 | $0.57 10-Q · filed 2023-08-21 | |||
| 2023-03-31 | $0.54 10-Q · filed 2023-05-15 | |||
| 2022-12-31 | $1.54 10-K · filed 2023-04-14 | |||
| 2022-09-30 | $1.54 10-Q · filed 2022-11-14 | |||
| 2022-06-30 | $2.84 10-Q · filed 2022-08-10 | |||
| 2022-03-31 | $5.64 10-Q · filed 2022-05-12 | |||
| 2021-12-31 | $5.81 10-K/A · filed 2023-04-28 | |||
| 2020-12-31 | $2.69 10-K/A · filed 2023-04-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Century Therapeutics, Inc. (IPSC) | United States | $0.306B | -4.02 |
| X4 Pharmaceuticals, Inc (XFOR) | United States | $0.297B | -4.99 |
| Inhibikase Therapeutics, Inc. (IKT) | United States | $0.296B | -4.44 |
| Liminatus Pharma, Inc. (LIMN) | United States | $0.282B | |
| FATE THERAPEUTICS INC (FATE) | United States | $0.280B | -2.51 |
| Lexeo Therapeutics, Inc. (LXEO) | United States | $0.278B | -4.19 |
| PALISADE BIO, INC. (PALI) | United States | $0.275B | -11.41 |
| Invivyd, Inc. (IVVD) | United States | $0.270B | -2.42 |
| Ocugen, Inc. (OCGN) | United States | $0.343B | -6.34 |
| SUTRO BIOPHARMA, INC. (STRO) | United States | $0.260B | -3.05 |